Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04174755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Study acronym: SWIFT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2025 to Jan 2027
    • Study completion date: Jan 2026 to Jul 2027
    • Site details revised
    v9
  2. Primary completion date: Nov 2024 to Nov 2025
    • Study completion date: Jan 2025 to Jan 2026
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2022 to Jun 22, 2022
    v6
  5. Start date: Jul 2021 to Jul 2022
    • Primary completion date: May 2024 to Nov 2024
    • Study completion date: Jul 2024 to Jan 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Jun 2022 to May 2024
    • Start date: Jul 2020 to Jul 2021
    • Study completion date: Feb 2023 to Jul 2024
    v4
  2. Start date: Feb 2020 to Jul 2020v3
  3. Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 4 of 9 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese PWH is still unexplored. The aim of this study is to assess the efficacy and safety of semaglutide in achieving greater weight loss compared to diet and excercise alone in obese PWH and to explore the effect of semaglutide on the immune function, markers of immune activation, viral reservoir, markers of glucose and lipid metabolism and gut microbiome.
Trial Details
NCT Number NCT04174755
Lead Sponsor University College Dublin
Collaborators: University of Copenhagen, Rush University Medical Center
Conditions
(from sponsor)		 Obesity, HIV-1-infection
Related terms Obesity, Weight Loss
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov